MEF2D and acute lymphoblastic leukemia: The most frequent FG in ALL was BCR-ABL1 (13.5%), followed by ETV6-RUNX1 (4.3%), EP300-ZNF384 (3.7%), TCF3-PBX1 (3.0%), KMT2A-AFF1 (2.5%), MEF2D-BCL9 (2.5%), STIL-TAL1 (1.8%), TCF3-HLF (1.8%), ZNF292-PNRC1 (1.8%), EBF1-PDGFRB (1.1%), PAX5-NOL4L (1.1%), PICALM-MLLT10 (1.1%), and TCF3-ZNF384 (1.1%).